Enliven Therapeutics, Inc. Overview
Pro stress-test →Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule inhibitors for oncology, with lead candidates ELVN-001 (CML) and ELVN-002 (HER2-driven cancers) currently in Phase 1 trials. The company leverages precision oncology to address unmet cancer treatment needs with a focus on improving both survival and patient quality of life.
Strategic Profile
Pro stress-test →Enliven positions itself as a precision oncology innovator combining clinically validated targets with differentiated chemistry to develop potentially first-in-class or best-in-class therapies. Recent leadership changes and strong cash position ($477.6M as of Q3 2025) support execution through 2029, enabling the company to advance its clinical programs toward key 2026 milestones.
Competitive Landscape
Pro stress-test →Enliven competes in the precision oncology space against established players developing kinase inhibitors and HER2-targeted therapies. Direct competitors include larger biopharmaceutical companies and other clinical-stage oncology programs, though Enliven's focus on validated targets and disciplined clinical design differentiates its approach in a competitive but large addressable market.
Industry Context
Enliven Therapeutics, Inc. operates in Biopharmaceutical/Precision Oncology.
Key facts
Headquarters: Boulder, Colorado · Revenue: $0